Advertisement
News
Advertisement

For a new DNA sequencer, a technical fix may have come too late

Tue, 07/03/2012 - 6:55pm
I-Micronews

A new technique dramatically increases the accuracy of the single-molecule DNA sequencing technology like PacBio’s, but it may still be too little to late for the biotechnology company, which has seen its shares drop from more than $16 to $2 since its 2010 IPO. The company’s value on the stock market is currently $43 million less than the amount of cash it has in the bank – meaning that Wall Street expects the company to spend a lot more before it rights itself – or to fail entirely.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading